

# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	15	10.0	150.1	(83.9-247.5)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	11.0	45.3	(14.6-105.6)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.6	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	26	38.3	68.0	(44.4-99.6)
Female	0	0.3	nc	(nc-nc)	Female	36	32.6	110.4	(77.3-152.9)
<b><u>Lung and Bronchus</u></b>									
Male	5	5.3	93.5	(30.1-218.1)					
Female	2	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	42.9	58.3	(37.7-86.0)	Male	26	26.1	99.7	(65.1-146.1)
Female	6	15.8	38.1	(13.9-82.9)	Female	25	20.1	124.7	(80.7-184.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.4	81.5	(29.8-177.3)	Male	13	8.4	154.8	(82.3-264.7)
Female	5	6.3	80.0	(25.8-186.6)	Female	6	7.0	85.9	(31.4-187.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	21	23.4	89.8	(55.5-137.2)
Female	164	162.3	101.0	(86.2-117.7)	Female	24	21.2	113.2	(72.5-168.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.0	nc	(nc-nc)	Male	15	18.2	82.3	(46.0-135.8)
<b><u>Colon / Rectum</u></b>					Female	8	8.9	90.2	(38.8-177.7)
Male	35	44.7	78.2	(54.5-108.8)	<b><u>Ovary</u></b>				
Female	31	47.3	65.5	(44.5-93.0)	Female	20	14.5	138.0	(84.3-213.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	10.9	nc	(nc-nc)	Male	12	14.8	81.2	(41.9-141.9)
Female	1	3.0	nc	(nc-nc)	Female	18	15.9	113.5	(67.2-179.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	140	134.3	104.3	(87.7-123.0)
Female	1	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	9.8	nc	(nc-nc)
Male	21	21.7	96.8	(59.9-148.0)	Female	8	6.1	131.0	(56.4-258.1)
Female	8	13.1	61.2	(26.4-120.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.6	nc	(nc-nc)
Male	3	6.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	10	9.0	110.6	(52.9-203.4)
<b><u>Leukemia</u></b>					Female	36	26.1	137.8	(96.5-190.8)
Male	19	16.4	115.5	(69.5-180.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	12.2	98.6	(50.9-172.3)	Female	30	36.9	81.4	(54.9-116.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	13.8	nc	(nc-nc)	Male	428	533.9	80.2	(72.7-88.1)
Female	4	4.8	nc	(nc-nc)	Female	503	558.0	90.1	(82.4-98.4)
<b><u>Lung and Bronchus</u></b>									
Male	35	74.9	46.7	(32.6-65.0)					
Female	48	81.3	59.1	(43.5-78.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	12.4	88.7	(44.2-158.7)
Female	0	0.1	nc	(nc-nc)	Female	5	11.7	42.9	(13.8-100.1)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.6	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lincoln

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	8.9	56.4	(18.2-131.7)	Male	5	5.1	98.4	(31.7-229.6)
Female	7	2.3	305.5	(122.4-629.4)	Female	7	3.3	214.3	(85.9-441.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.6	108.6	(35.0-253.3)
Female	41	25.2	162.9	(116.9-221.0)	Female	5	3.2	154.7	(49.9-361.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	5	3.3	153.7	(49.5-358.7)
<b><u>Colon / Rectum</u></b>					Female	2	1.4	nc	(nc-nc)
Male	8	9.0	88.9	(38.3-175.3)	<b><u>Ovary</u></b>				
Female	8	7.2	111.2	(47.9-219.1)	Female	5	2.2	222.3	(71.6-518.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	6	2.9	204.0	(74.5-444.1)
Female	0	0.4	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	45	22.7	198.5	(144.8-265.7)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.0	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.7	nc	(nc-nc)
Male	6	3.4	179.1	(65.4-389.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	2.0	351.8	(141.0-724.9)	Female	9	5.7	158.8	(72.5-301.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	122	101.0	120.8	(100.3-144.3)
Female	1	0.7	nc	(nc-nc)	Female	122	86.0	141.9	(117.8-169.4)
<b><u>Lung and Bronchus</u></b>									
Male	7	14.4	48.8	(19.5-100.5)					
Female	8	11.6	68.7	(29.6-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Littleton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	8.8	147.7	(78.6-252.7)	Male	4	6.0	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.4	167.1	(76.3-317.3)
Female	33	42.0	78.6	(54.1-110.4)	Female	6	5.3	113.9	(41.6-248.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.2	nc	(nc-nc)
Male	6	10.0	60.1	(21.9-130.8)	<b><u>Ovary</u></b>				
Female	9	11.6	77.3	(35.3-146.8)	Female	4	3.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	5	3.2	156.4	(50.4-365.0)
Female	0	0.7	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	35	31.1	112.4	(78.3-156.4)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	7.5	107.3	(46.2-211.5)
Male	2	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	11	9.4	117.5	(58.6-210.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	124	121.6	102.0	(84.8-121.6)
Female	2	1.2	nc	(nc-nc)	Female	108	141.3	76.5	(62.7-92.3)
<b><u>Lung and Bronchus</u></b>									
Male	21	16.3	128.8	(79.7-196.9)					
Female	9	19.7	45.6	(20.8-86.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	22.2	53.9	(27.8-94.2)	Male	20	13.2	152.0	(92.8-234.7)
Female	7	7.8	89.3	(35.8-183.9)	Female	13	9.8	132.4	(70.4-226.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	8	11.9	67.4	(29.0-132.8)
Female	78	76.4	102.1	(80.7-127.5)	Female	14	10.3	135.4	(74.0-227.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	4	9.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	4.3	nc	(nc-nc)
Male	13	23.1	56.3	(29.9-96.2)	<b><u>Ovary</u></b>				
Female	13	24.1	54.0	(28.7-92.3)	Female	6	7.0	85.7	(31.3-186.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.5	nc	(nc-nc)	Male	3	7.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	4	8.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	66	66.5	99.3	(76.8-126.3)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.0	119.1	(43.5-259.3)
Male	9	10.7	84.2	(38.4-159.8)	Female	2	3.1	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.9	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	12.6	55.5	(22.2-114.3)
Male	12	8.3	144.6	(74.6-252.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	6.2	nc	(nc-nc)	Female	9	17.0	53.0	(24.2-100.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.9	nc	(nc-nc)	Male	215	269.2	79.9	(69.6-91.3)
Female	5	2.3	216.8	(69.9-506.0)	Female	225	269.6	83.4	(72.9-95.1)
<b><u>Lung and Bronchus</u></b>									
Male	19	37.9	50.1	(30.2-78.3)					
Female	22	38.4	57.2	(35.9-86.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	82	81.8	100.3	(79.7-124.5)	Male	34	57.0	59.7	(41.3-83.4)
Female	46	33.0	139.5	(102.1-186.1)	Female	34	51.1	66.6	(46.1-93.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	17	19.3	87.9	(51.2-140.8)	Male	21	17.2	122.3	(75.7-187.0)
Female	16	16.3	98.3	(56.2-159.6)	Female	21	14.9	141.1	(87.3-215.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	53	51.2	103.6	(77.6-135.5)
Female	312	373.9	83.5	(74.4-93.2)	Female	32	47.2	67.7	(46.3-95.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	14.1	127.8	(75.7-202.0)	Male	52	41.9	124.1	(92.7-162.7)
<b><u>Colon / Rectum</u></b>					Female	7	19.8	35.4	(14.2-73.0)
Male	91	92.7	98.2	(79.0-120.5)	<b><u>Ovary</u></b>				
Female	102	101.2	100.8	(82.2-122.4)	Female	28	33.5	83.5	(55.5-120.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	23	22.4	102.5	(64.9-153.8)	Male	25	29.5	84.8	(54.8-125.1)
Female	4	6.4	nc	(nc-nc)	Female	22	33.0	66.7	(41.8-100.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	11	9.0	122.5	(61.1-219.1)	Male	223	287.8	77.5	(67.6-88.3)
Female	4	7.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	24	19.9	120.7	(77.3-179.6)
Male	46	49.2	93.6	(68.5-124.8)	Female	28	13.0	215.4	(143.1-311.3)
Female	38	29.8	127.3	(90.1-174.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	15	18.1	82.7	(46.2-136.4)
Male	19	13.3	142.5	(85.8-222.6)	<b><u>Thyroid</u></b>				
Female	8	4.3	186.0	(80.1-366.4)	Male	22	25.1	87.6	(54.9-132.6)
<b><u>Leukemia</u></b>					Female	74	79.5	93.1	(73.1-116.8)
Male	32	36.4	87.8	(60.1-124.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	41	29.1	140.8	(101.0-191.0)	Female	80	83.1	96.3	(76.3-119.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	61	30.6	199.3	(152.5-256.1)	Male	1163	1142.6	101.8	(96.0-107.8)
Female	7	10.6	66.2	(26.5-136.5)	Female	1221	1276.9	95.6	(90.3-101.1)
<b><u>Lung and Bronchus</u></b>									
Male	185	148.4	124.7	(107.4-144.0)					
Female	190	173.3	109.6	(94.6-126.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	26.1	111.3	(74.5-159.8)	Male	15	16.6	90.3	(50.5-148.9)
Female	6	10.2	58.9	(21.5-128.2)	Female	15	13.3	113.0	(63.2-186.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.8	101.1	(56.5-166.7)
Female	79	106.0	74.5	(59.0-92.9)	Female	10	13.8	72.6	(34.7-133.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.3	149.4	(48.1-348.6)	Male	7	12.1	58.1	(23.3-119.6)
<b><u>Colon / Rectum</u></b>					Female	2	5.8	nc	(nc-nc)
Male	34	28.3	119.9	(83.0-167.6)	<b><u>Ovary</u></b>				
Female	25	30.3	82.5	(53.4-121.7)	Female	11	9.5	116.3	(58.0-208.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.9	nc	(nc-nc)	Male	4	9.2	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	12	10.2	117.3	(60.6-205.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	71	86.7	81.9	(63.9-103.3)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	6.1	114.7	(45.9-236.3)
Male	18	14.0	128.3	(76.0-202.7)	Female	3	3.9	nc	(nc-nc)
Female	6	8.6	70.1	(25.6-152.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.3	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	17.8	28.2	(9.1-65.7)
Male	6	10.2	58.7	(21.4-127.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.9	75.7	(27.6-164.8)	Female	21	24.2	86.9	(53.8-132.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	9.0	89.1	(38.4-175.5)	Male	290	338.9	85.6	(76.0-96.0)
Female	3	3.1	nc	(nc-nc)	Female	284	364.2	78.0	(69.2-87.6)
<b><u>Lung and Bronchus</u></b>									
Male	32	45.8	69.8	(47.7-98.6)					
Female	38	53.1	71.5	(50.6-98.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	11.9	58.9	(23.6-121.4)	Male	6	7.7	77.5	(28.3-168.6)
Female	4	3.9	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	6	2.5	242.9	(88.7-528.7)
Female	3	1.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
Female	56	47.6	117.6	(88.9-152.8)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	5	5.8	85.8	(27.7-200.2)
<b><u>Colon / Rectum</u></b>					Female	0	2.5	nc	(nc-nc)
Male	16	13.3	120.2	(68.6-195.1)	<b><u>Ovary</u></b>				
Female	12	12.1	99.0	(51.1-172.9)	Female	3	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	43	41.4	103.8	(75.1-139.8)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.8	nc	(nc-nc)
Male	3	6.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.6	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	8.6	69.5	(25.4-151.2)
Male	8	4.7	168.5	(72.5-331.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.3	nc	(nc-nc)	Female	17	11.3	150.6	(87.7-241.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	156	159.4	97.9	(83.1-114.5)
Female	3	1.3	nc	(nc-nc)	Female	148	156.1	94.8	(80.1-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	24	21.3	112.9	(72.3-168.1)					
Female	16	21.1	75.7	(43.2-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	65	71.2	91.2	(70.4-116.3)	Male	43	48.7	88.2	(63.8-118.8)
Female	24	29.4	81.6	(52.3-121.4)	Female	32	44.6	71.8	(49.1-101.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	21	16.4	128.4	(79.5-196.3)	Male	26	14.9	174.7	(114.1-256.0)
Female	15	14.3	105.1	(58.8-173.4)	Female	13	13.3	98.0	(52.1-167.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	2.5	199.1	(64.2-464.7)	Male	54	44.0	122.8	(92.2-160.2)
Female	319	332.7	95.9	(85.6-107.0)	Female	49	41.9	117.1	(86.6-154.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	12.2	139.8	(81.4-223.9)	Male	50	35.8	139.7	(103.7-184.2)
<b><u>Colon / Rectum</u></b>					Female	20	17.6	113.6	(69.4-175.4)
Male	110	81.0	135.8	(111.6-163.7)	<b><u>Ovary</u></b>				
Female	109	90.1	121.0	(99.4-146.0)	Female	25	29.8	83.8	(54.2-123.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	24	19.3	124.2	(79.5-184.8)	Male	23	25.5	90.2	(57.2-135.4)
Female	6	5.7	105.4	(38.5-229.4)	Female	24	29.4	81.6	(52.3-121.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	7.2	69.2	(22.3-161.5)	Male	305	247.5	123.2	(109.8-137.9)
Female	2	6.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	17.2	92.9	(53.1-150.9)
Male	41	42.3	96.9	(69.5-131.5)	Female	21	11.6	181.8	(112.5-277.9)
Female	23	26.5	86.7	(54.9-130.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	17	14.2	119.6	(69.6-191.5)
Male	17	11.4	148.9	(86.7-238.4)	<b><u>Thyroid</u></b>				
Female	4	3.9	nc	(nc-nc)	Male	17	21.1	80.5	(46.9-129.0)
<b><u>Leukemia</u></b>					Female	53	68.3	77.6	(58.1-101.5)
Male	40	31.3	128.0	(91.4-174.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	32	25.7	124.7	(85.3-176.0)	Female	71	74.1	95.8	(74.8-120.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	56	26.0	215.1	(162.5-279.4)	Male	1231	982.5	125.3	(118.4-132.5)
Female	18	9.4	191.3	(113.3-302.4)	Female	1159	1132.6	102.3	(96.5-108.4)
<b><u>Lung and Bronchus</u></b>									
Male	195	128.1	152.2	(131.6-175.1)					
Female	179	155.2	115.3	(99.1-133.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	15.9	94.3	(52.7-155.5)	Male	22	10.0	220.5	(138.1-333.8)
Female	9	5.0	178.5	(81.4-338.9)	Female	12	6.8	175.8	(90.7-307.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.2	155.4	(50.1-362.7)
Female	5	2.1	233.7	(75.3-545.3)	Female	4	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.8	158.8	(86.8-266.5)
Female	50	55.7	89.7	(66.6-118.3)	Female	15	6.9	216.2	(120.9-356.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.9	nc	(nc-nc)
Male	13	16.8	77.5	(41.2-132.5)	<b><u>Ovary</u></b>				
Female	22	15.1	145.8	(91.4-220.8)	Female	7	4.9	143.5	(57.5-295.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	6	5.5	108.9	(39.8-237.1)
Female	0	1.0	nc	(nc-nc)	Female	6	5.0	119.6	(43.7-260.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	46	51.6	89.1	(65.2-118.8)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.7	nc	(nc-nc)
Male	11	8.3	131.9	(65.8-236.1)	Female	2	1.9	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.6	320.6	(103.3-748.2)
Male	3	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.6	167.7	(61.2-365.1)
<b><u>Leukemia</u></b>					Female	15	9.6	156.5	(87.5-258.2)
Male	10	6.1	165.0	(79.0-303.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.0	125.9	(40.6-293.9)	Female	16	12.5	127.6	(72.9-207.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	200	203.0	98.5	(85.4-113.2)
Female	1	1.6	nc	(nc-nc)	Female	221	186.8	118.3	(103.2-135.0)
<b><u>Lung and Bronchus</u></b>									
Male	20	28.7	69.6	(42.5-107.5)					
Female	28	26.8	104.3	(69.3-150.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	48.6	55.5	(36.6-80.8)	Male	8	33.6	23.8	(10.3-46.9)
Female	26	19.3	134.8	(88.0-197.5)	Female	20	30.2	66.2	(40.4-102.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	10.9	nc	(nc-nc)	Male	7	10.1	69.0	(27.6-142.1)
Female	8	9.4	85.5	(36.8-168.4)	Female	7	8.7	80.1	(32.1-165.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	40	30.0	133.2	(95.1-181.3)
Female	193	221.6	87.1	(75.2-100.3)	Female	23	27.8	82.7	(52.4-124.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	13	8.5	153.4	(81.6-262.3)	Male	23	24.3	94.7	(60.0-142.2)
<b><u>Colon / Rectum</u></b>					Female	9	11.7	77.0	(35.1-146.2)
Male	71	54.6	130.0	(101.5-163.9)	<b><u>Ovary</u></b>				
Female	79	59.9	131.8	(104.3-164.2)	Female	16	19.9	80.5	(46.0-130.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	13.1	114.2	(63.9-188.4)	Male	21	17.3	121.2	(75.0-185.3)
Female	8	3.7	216.4	(93.2-426.4)	Female	15	19.3	77.7	(43.5-128.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	129	165.3	78.0	(65.1-92.7)
Female	5	4.4	113.1	(36.4-263.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	11.7	127.8	(71.5-210.8)
Male	34	28.6	119.0	(82.4-166.3)	Female	6	7.7	78.1	(28.5-170.0)
Female	18	17.4	103.2	(61.2-163.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	10.8	73.8	(31.8-145.4)
Male	11	7.7	142.3	(70.9-254.6)	<b><u>Thyroid</u></b>				
Female	5	2.5	196.7	(63.4-458.9)	Male	15	14.8	101.4	(56.7-167.2)
<b><u>Leukemia</u></b>					Female	62	47.7	129.9	(99.6-166.5)
Male	24	20.9	114.7	(73.5-170.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	16.7	95.7	(54.7-155.5)	Female	51	48.8	104.4	(77.7-137.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	24	17.7	135.5	(86.8-201.7)	Male	639	666.6	95.9	(88.6-103.6)
Female	13	6.2	211.0	(112.2-360.8)	Female	772	752.3	102.6	(95.5-110.1)
<b><u>Lung and Bronchus</u></b>									
Male	117	86.9	134.6	(111.3-161.3)					
Female	111	100.7	110.3	(90.7-132.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	8.1	nc	(nc-nc)	Male	14	4.7	295.1	(161.2-495.2)
Female	1	2.6	nc	(nc-nc)	Female	5	3.3	150.1	(48.4-350.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	32	27.7	115.6	(79.0-163.2)	Female	3	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	5	8.3	59.9	(19.3-139.8)	<b><u>Ovary</u></b>				
Female	5	7.5	66.8	(21.5-155.8)	Female	2	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	28	22.9	122.5	(81.4-177.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.8	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	4.4	203.1	(92.7-385.7)
Male	1	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	8	6.3	126.8	(54.6-249.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	89	96.1	92.6	(74.4-114.0)
Female	0	0.8	nc	(nc-nc)	Female	95	93.3	101.8	(82.4-124.5)
<b><u>Lung and Bronchus</u></b>									
Male	6	13.7	43.9	(16.0-95.5)					
Female	10	14.1	71.0	(34.0-130.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	15.6	128.2	(78.3-197.9)	Male	26	11.6	223.6	(146.0-327.6)
Female	0	5.6	nc	(nc-nc)	Female	20	10.3	193.6	(118.2-299.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.1	193.7	(83.4-381.6)	Male	3	3.5	nc	(nc-nc)
Female	7	3.3	214.9	(86.1-442.8)	Female	1	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	14	10.6	132.6	(72.5-222.6)
Female	89	80.2	110.9	(89.1-136.5)	Female	4	8.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.2	nc	(nc-nc)	Male	11	9.2	119.5	(59.6-213.9)
<b><u>Colon / Rectum</u></b>					Female	1	3.8	nc	(nc-nc)
Male	27	19.3	140.0	(92.2-203.7)	<b><u>Ovary</u></b>				
Female	28	18.5	151.6	(100.7-219.2)	Female	7	6.9	102.0	(40.8-210.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	9	5.5	162.6	(74.2-308.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	57	58.5	97.4	(73.7-126.1)
Female	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.0	150.6	(55.0-327.8)
Male	14	10.5	132.9	(72.6-222.9)	Female	3	2.3	nc	(nc-nc)
Female	9	5.9	153.6	(70.1-291.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.5	170.0	(62.1-370.1)
Male	0	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	16	5.6	284.1	(162.3-461.4)
<b><u>Leukemia</u></b>					Female	19	17.9	106.3	(64.0-166.0)
Male	9	7.4	121.6	(55.5-230.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	5.3	188.5	(90.2-346.7)	Female	14	17.4	80.3	(43.9-134.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	6.5	92.4	(33.7-201.2)	Male	279	231.9	120.3	(106.6-135.3)
Female	3	1.9	nc	(nc-nc)	Female	290	251.3	115.4	(102.5-129.5)
<b><u>Lung and Bronchus</u></b>									
Male	32	28.6	112.1	(76.6-158.2)					
Female	38	30.2	125.8	(89.0-172.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	24.9	96.5	(61.8-143.5)	Male	38	15.5	244.7	(173.1-335.8)
Female	13	8.8	147.7	(78.6-252.7)	Female	22	12.1	181.3	(113.6-274.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	4.4	nc	(nc-nc)	Male	8	5.0	160.9	(69.3-317.1)
Female	3	3.8	nc	(nc-nc)	Female	8	4.0	200.1	(86.2-394.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	13	13.9	93.9	(49.9-160.5)
Female	122	99.4	122.7	(101.9-146.6)	Female	11	12.3	89.8	(44.7-160.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.2	nc	(nc-nc)	Male	11	11.0	99.6	(49.7-178.3)
<b><u>Colon / Rectum</u></b>					Female	6	5.3	114.1	(41.7-248.5)
Male	32	26.2	122.0	(83.4-172.2)	<b><u>Ovary</u></b>				
Female	17	26.4	64.3	(37.5-103.0)	Female	6	8.8	68.5	(25.0-149.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.5	92.7	(33.8-201.7)	Male	13	8.6	150.4	(80.0-257.1)
Female	3	1.7	nc	(nc-nc)	Female	14	8.8	159.2	(86.9-267.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	96	81.0	118.5	(96.0-144.8)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	5.8	121.3	(48.6-250.0)
Male	11	13.2	83.6	(41.7-149.5)	Female	1	3.4	nc	(nc-nc)
Female	5	7.8	63.9	(20.6-149.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.3	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	9	5.6	160.0	(73.0-303.8)
<b><u>Leukemia</u></b>					Female	17	17.1	99.6	(58.0-159.5)
Male	11	9.7	113.9	(56.8-203.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.1	141.6	(67.8-260.4)	Female	20	22.9	87.3	(53.3-134.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	8.3	nc	(nc-nc)	Male	338	317.6	106.4	(95.4-118.4)
Female	2	2.8	nc	(nc-nc)	Female	360	331.2	108.7	(97.8-120.5)
<b><u>Lung and Bronchus</u></b>									
Male	25	44.4	56.3	(36.4-83.1)					
Female	38	47.0	80.9	(57.3-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.2	nc	(nc-nc)	Male	8	4.5	179.7	(77.4-354.0)
Female	4	2.9	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.0	201.9	(86.9-397.9)
Female	33	26.2	126.1	(86.8-177.0)	Female	3	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.5	nc	(nc-nc)
Male	8	7.5	107.3	(46.2-211.5)	<b><u>Ovary</u></b>				
Female	10	8.6	115.8	(55.4-213.0)	Female	0	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	23	27.0	85.1	(54.0-127.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.9	nc	(nc-nc)
Male	10	2.7	368.9	(176.6-678.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.2	nc	(nc-nc)	Female	6	6.1	98.5	(36.0-214.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	86	95.3	90.2	(72.2-111.4)
Female	1	0.8	nc	(nc-nc)	Female	101	94.2	107.2	(87.3-130.2)
<b><u>Lung and Bronchus</u></b>									
Male	8	13.0	61.3	(26.4-120.9)					
Female	18	13.4	134.3	(79.6-212.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	38.1	104.9	(74.9-142.8)	Male	25	25.6	97.7	(63.2-144.3)
Female	9	13.3	67.9	(31.0-128.9)	Female	15	20.1	74.7	(41.8-123.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	8.0	74.7	(27.3-162.6)	Male	5	7.9	63.1	(20.3-147.2)
Female	8	6.2	128.5	(55.3-253.3)	Female	5	6.0	82.8	(26.7-193.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	19	22.8	83.3	(50.1-130.1)
Female	140	154.0	90.9	(76.5-107.3)	Female	17	19.0	89.3	(52.0-143.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.6	159.9	(73.0-303.6)	Male	18	18.5	97.2	(57.6-153.6)
<b><u>Colon / Rectum</u></b>					Female	18	8.0	224.3	(132.9-354.5)
Male	46	42.4	108.5	(79.4-144.7)	<b><u>Ovary</u></b>				
Female	61	40.9	149.1	(114.0-191.5)	Female	16	13.5	118.3	(67.6-192.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	10.2	117.5	(60.6-205.2)	Male	9	13.5	66.8	(30.5-126.8)
Female	5	2.6	194.6	(62.7-454.0)	Female	14	13.3	105.5	(57.6-177.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	3.3	181.9	(66.4-396.0)	Male	128	126.9	100.9	(84.1-119.9)
Female	2	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	9.1	76.9	(30.8-158.5)
Male	25	21.8	114.5	(74.0-169.0)	Female	6	5.2	115.1	(42.0-250.6)
Female	10	12.1	82.8	(39.6-152.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	6.4	nc	(nc-nc)
Male	6	6.0	100.5	(36.7-218.8)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	10	10.6	94.8	(45.4-174.3)
<b><u>Leukemia</u></b>					Female	38	30.8	123.5	(87.4-169.6)
Male	17	16.1	105.9	(61.6-169.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	11.3	106.6	(55.0-186.3)	Female	37	34.5	107.4	(75.6-148.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	13.7	80.1	(40.0-143.4)	Male	478	511.1	93.5	(85.3-102.3)
Female	7	4.3	163.3	(65.4-336.4)	Female	551	515.7	106.8	(98.1-116.2)
<b><u>Lung and Bronchus</u></b>									
Male	48	68.4	70.1	(51.7-93.0)					
Female	71	70.0	101.4	(79.2-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	26.4	83.2	(52.1-126.0)	Male	32	17.7	180.8	(123.6-255.2)
Female	11	9.2	119.8	(59.7-214.3)	Female	27	14.2	190.1	(125.3-276.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.5	164.1	(74.9-311.4)	Male	10	5.6	179.5	(85.9-330.0)
Female	6	4.4	135.7	(49.6-295.4)	Female	3	4.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	11	15.9	69.1	(34.4-123.6)
Female	139	116.3	119.5	(100.5-141.1)	Female	9	13.6	66.1	(30.2-125.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.9	127.1	(41.0-296.7)	Male	10	14.0	71.4	(34.2-131.4)
<b><u>Colon / Rectum</u></b>					Female	5	5.9	84.5	(27.2-197.2)
Male	25	29.9	83.5	(54.0-123.2)	<b><u>Ovary</u></b>				
Female	29	27.7	104.6	(70.0-150.2)	Female	12	10.1	119.2	(61.5-208.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.6	65.8	(21.2-153.5)	Male	13	9.8	132.9	(70.7-227.2)
Female	0	1.9	nc	(nc-nc)	Female	13	9.2	142.0	(75.5-242.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	119	102.3	116.4	(96.4-139.3)
Female	4	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.4	93.3	(34.1-203.1)
Male	23	16.0	143.6	(91.0-215.5)	Female	3	3.5	nc	(nc-nc)
Female	6	8.9	67.7	(24.7-147.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.4	nc	(nc-nc)
Male	1	4.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	7	7.3	95.7	(38.3-197.1)
<b><u>Leukemia</u></b>					Female	25	21.4	116.6	(75.5-172.2)
Male	12	10.9	109.7	(56.6-191.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	7.6	nc	(nc-nc)	Female	21	27.4	76.7	(47.5-117.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	10.2	117.4	(60.6-205.0)	Male	389	372.1	104.5	(94.4-115.5)
Female	1	3.2	nc	(nc-nc)	Female	407	374.9	108.6	(98.3-119.6)
<b><u>Lung and Bronchus</u></b>									
Male	45	48.4	93.0	(67.8-124.5)					
Female	59	51.7	114.1	(86.9-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	22.7	118.9	(78.3-173.0)	Male	16	13.4	119.4	(68.2-193.8)
Female	8	8.7	91.8	(39.5-181.0)	Female	20	10.3	193.4	(118.1-298.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	5	4.4	114.0	(36.8-266.1)
Female	3	3.2	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	17	11.8	144.2	(83.9-230.8)
Female	80	84.0	95.2	(75.5-118.5)	Female	16	11.3	141.7	(80.9-230.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	12	8.8	135.7	(70.0-237.1)
<b><u>Colon / Rectum</u></b>					Female	4	4.7	nc	(nc-nc)
Male	18	22.5	80.0	(47.4-126.4)	<b><u>Ovary</u></b>				
Female	25	24.6	101.8	(65.9-150.3)	Female	7	7.6	92.1	(36.9-189.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.6	88.5	(28.5-206.6)	Male	9	7.6	117.7	(53.7-223.4)
Female	0	1.7	nc	(nc-nc)	Female	8	8.6	93.1	(40.1-183.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	79	69.3	114.0	(90.3-142.1)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.0	nc	(nc-nc)
Male	13	10.8	120.3	(64.0-205.7)	Female	2	3.2	nc	(nc-nc)
Female	8	7.1	112.6	(48.5-221.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	12.4	72.6	(33.1-137.8)
Male	5	8.2	60.7	(19.5-141.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	6.4	156.5	(74.9-287.7)	Female	16	19.8	80.8	(46.1-131.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	6.9	86.6	(31.6-188.6)	Male	285	274.1	104.0	(92.2-116.8)
Female	1	2.6	nc	(nc-nc)	Female	299	295.9	101.1	(89.9-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	34	40.4	84.1	(58.2-117.5)					
Female	50	47.0	106.3	(78.9-140.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	7.8	128.2	(61.4-235.9)	Male	7	4.9	142.7	(57.2-294.1)
Female	3	2.7	nc	(nc-nc)	Female	6	3.6	167.2	(61.1-364.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
Female	45	29.9	150.5	(109.8-201.4)	Female	5	3.7	136.2	(43.9-317.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	11	3.4	323.9	(161.4-579.5)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	10	8.0	125.0	(59.8-229.8)	<b><u>Ovary</u></b>				
Female	11	7.7	143.1	(71.3-256.1)	Female	6	2.6	231.2	(84.4-503.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	44	26.1	168.8	(122.6-226.6)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.9	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	12	6.9	173.7	(89.7-303.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	129	100.3	128.6	(107.3-152.8)
Female	1	0.8	nc	(nc-nc)	Female	122	99.2	122.9	(102.1-146.8)
<b><u>Lung and Bronchus</u></b>									
Male	16	14.5	110.4	(63.1-179.4)					
Female	12	14.6	82.0	(42.3-143.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	11.5	112.8	(60.0-192.9)	Male	7	7.4	94.7	(37.9-195.1)
Female	2	3.6	nc	(nc-nc)	Female	6	5.5	108.4	(39.6-236.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.6	120.6	(51.9-237.6)
Female	49	42.4	115.6	(85.5-152.8)	Female	4	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	5	5.3	93.7	(30.2-218.6)
<b><u>Colon / Rectum</u></b>					Female	2	2.2	nc	(nc-nc)
Male	18	12.5	144.5	(85.6-228.4)	<b><u>Ovary</u></b>				
Female	19	11.1	171.6	(103.3-268.0)	Female	2	3.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	5	3.6	138.8	(44.7-323.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	29	38.0	76.2	(51.1-109.5)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.7	nc	(nc-nc)
Male	3	6.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	5	3.3	151.3	(48.8-353.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.5	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.5	117.3	(56.2-215.7)
Male	3	4.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.1	162.7	(52.4-379.6)	Female	5	9.7	51.7	(16.7-120.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	126	150.4	83.8	(69.8-99.7)
Female	2	1.2	nc	(nc-nc)	Female	154	141.1	109.2	(92.6-127.8)
<b><u>Lung and Bronchus</u></b>									
Male	9	20.4	44.1	(20.1-83.7)					
Female	19	18.8	101.2	(60.9-158.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	13.2	60.7	(26.1-119.5)	Male	10	8.7	115.6	(55.3-212.5)
Female	4	3.9	nc	(nc-nc)	Female	9	6.2	146.0	(66.6-277.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	54	49.8	108.4	(81.4-141.4)	Female	5	5.7	87.4	(28.2-203.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	7	6.6	106.3	(42.6-219.0)
<b><u>Colon / Rectum</u></b>					Female	1	2.5	nc	(nc-nc)
Male	14	14.7	95.0	(51.9-159.5)	<b><u>Ovary</u></b>				
Female	13	12.5	104.2	(55.4-178.2)	Female	4	4.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	59	46.2	127.8	(97.3-164.9)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.2	nc	(nc-nc)
Male	6	7.5	79.7	(29.1-173.4)	Female	2	1.6	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.5	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	9.5	94.4	(43.1-179.1)
Male	6	5.4	111.4	(40.7-242.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	3.3	240.4	(103.5-473.7)	Female	9	11.3	79.9	(36.5-151.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	4.9	nc	(nc-nc)	Male	151	177.7	85.0	(72.0-99.7)
Female	1	1.3	nc	(nc-nc)	Female	152	159.5	95.3	(80.7-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	11	23.4	47.1	(23.5-84.2)					
Female	14	20.3	69.0	(37.7-115.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	63	57.2	110.1	(84.6-140.8)	Male	25	36.5	68.4	(44.3-101.0)
Female	21	22.5	93.2	(57.7-142.5)	Female	25	32.1	77.9	(50.4-115.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	11.0	109.6	(56.6-191.4)	Male	10	11.3	88.8	(42.5-163.3)
Female	11	9.7	112.9	(56.3-202.0)	Female	11	10.0	109.5	(54.6-196.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	29	32.6	88.8	(59.5-127.6)
Female	243	237.4	102.4	(89.9-116.1)	Female	22	31.3	70.4	(44.1-106.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	8.4	82.9	(33.2-170.9)	Male	33	24.7	133.8	(92.1-187.9)
<b><u>Colon / Rectum</u></b>					Female	14	12.9	108.2	(59.1-181.6)
Male	72	60.9	118.2	(92.5-148.8)	<b><u>Ovary</u></b>				
Female	81	67.4	120.2	(95.5-149.4)	Female	25	21.5	116.3	(75.3-171.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	14.3	90.7	(48.2-155.1)	Male	18	19.6	91.8	(54.4-145.1)
Female	7	4.3	161.8	(64.8-333.3)	Female	13	22.6	57.6	(30.7-98.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	5.0	99.5	(32.1-232.3)	Male	155	174.1	89.0	(75.6-104.2)
Female	5	4.4	112.9	(36.4-263.5)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	13.2	120.9	(69.0-196.3)
Male	27	29.6	91.2	(60.1-132.6)	Female	9	8.7	103.6	(47.3-196.6)
Female	24	19.2	124.7	(79.9-185.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	10.0	130.2	(69.3-222.7)
Male	10	8.3	120.5	(57.7-221.7)	<b><u>Thyroid</u></b>				
Female	2	2.8	nc	(nc-nc)	Male	12	14.1	85.1	(43.9-148.6)
<b><u>Leukemia</u></b>					Female	46	46.7	98.5	(72.1-131.3)
Male	27	23.0	117.6	(77.5-171.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	25	18.3	137.0	(88.6-202.2)	Female	56	53.8	104.2	(78.7-135.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	19	18.5	102.7	(61.8-160.3)	Male	717	725.2	98.9	(91.8-106.4)
Female	8	7.1	113.2	(48.8-223.1)	Female	867	826.2	104.9	(98.1-112.2)
<b><u>Lung and Bronchus</u></b>									
Male	101	99.8	101.2	(82.4-122.9)					
Female	135	117.6	114.8	(96.2-135.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	11.9	117.4	(64.2-197.1)	Male	7	8.1	86.7	(34.7-178.6)
Female	2	4.4	nc	(nc-nc)	Female	5	6.8	73.5	(23.7-171.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	7.3	164.0	(84.7-286.6)
Female	54	53.4	101.1	(75.9-131.9)	Female	6	6.4	94.5	(34.5-205.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.7	nc	(nc-nc)
Male	17	13.7	124.1	(72.3-198.8)	<b><u>Ovary</u></b>				
Female	16	14.2	112.8	(64.4-183.1)	Female	6	4.7	127.0	(46.4-276.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.4	206.1	(82.6-424.6)	Male	2	4.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	4.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	43	44.7	96.2	(69.6-129.6)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.9	nc	(nc-nc)
Male	5	7.3	68.7	(22.1-160.2)	Female	0	1.8	nc	(nc-nc)
Female	0	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	10.5	114.6	(59.1-200.1)
Male	3	5.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.8	nc	(nc-nc)	Female	10	11.8	84.4	(40.4-155.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.7	nc	(nc-nc)	Male	153	167.7	91.2	(77.4-106.9)
Female	1	1.4	nc	(nc-nc)	Female	161	174.9	92.0	(78.4-107.4)
<b><u>Lung and Bronchus</u></b>									
Male	14	21.7	64.6	(35.3-108.5)					
Female	25	22.3	112.3	(72.6-165.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	28.4	81.1	(51.4-121.7)	Male	22	18.6	118.4	(74.2-179.3)
Female	13	11.2	116.0	(61.7-198.3)	Female	21	15.8	133.1	(82.4-203.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.6	88.5	(28.5-206.6)	Male	5	5.8	86.2	(27.8-201.2)
Female	7	4.8	144.6	(57.9-298.0)	Female	4	5.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	20	16.6	120.4	(73.5-186.0)
Female	124	120.5	102.9	(85.6-122.7)	Female	16	15.6	102.7	(58.6-166.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.2	nc	(nc-nc)	Male	13	13.3	97.9	(52.1-167.4)
<b><u>Colon / Rectum</u></b>					Female	5	6.5	76.5	(24.7-178.6)
Male	46	31.0	148.2	(108.5-197.6)	<b><u>Ovary</u></b>				
Female	35	34.6	101.3	(70.5-140.8)	Female	10	10.8	92.4	(44.2-169.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	7.5	160.0	(82.6-279.5)	Male	12	10.0	120.3	(62.1-210.1)
Female	1	2.2	nc	(nc-nc)	Female	16	11.5	139.6	(79.8-226.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	91	94.7	96.1	(77.3-118.0)
Female	2	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.7	74.8	(24.1-174.5)
Male	14	16.0	87.5	(47.8-146.7)	Female	5	4.5	111.8	(36.0-260.9)
Female	10	9.6	104.6	(50.1-192.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.2	nc	(nc-nc)
Male	9	4.3	207.0	(94.4-392.9)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	9	7.6	119.2	(54.4-226.2)
<b><u>Leukemia</u></b>					Female	25	22.6	110.6	(71.6-163.3)
Male	19	11.6	164.2	(98.8-256.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	9.2	97.9	(44.7-185.9)	Female	31	27.1	114.4	(77.7-162.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	9.7	nc	(nc-nc)	Male	397	374.8	105.9	(95.8-116.9)
Female	4	3.5	nc	(nc-nc)	Female	419	413.3	101.4	(91.9-111.6)
<b><u>Lung and Bronchus</u></b>									
Male	50	50.7	98.6	(73.2-130.0)					
Female	46	56.7	81.1	(59.4-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	6.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	21	22.9	91.7	(56.7-140.2)	Female	7	2.5	281.8	(112.9-580.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	2	7.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	5.0	99.2	(32.0-231.6)	Female	2	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	24	22.4	107.2	(68.7-159.6)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.6	nc	(nc-nc)
Male	6	2.7	219.8	(80.2-478.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	7	5.1	137.0	(54.9-282.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	58	88.6	65.4	(49.7-84.6)
Female	1	0.6	nc	(nc-nc)	Female	77	70.5	109.2	(86.2-136.5)
<b><u>Lung and Bronchus</u></b>									
Male	4	11.5	nc	(nc-nc)					
Female	7	8.8	79.1	(31.7-163.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.7	75.0	(24.2-175.1)	Male	5	4.5	112.2	(36.2-261.9)
Female	5	2.3	220.3	(71.0-514.2)	Female	4	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	20	29.2	68.5	(41.8-105.8)	Female	3	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	9	7.4	121.1	(55.2-229.8)	<b><u>Ovary</u></b>				
Female	8	7.1	113.3	(48.8-223.3)	Female	5	2.5	197.2	(63.5-460.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	21	24.4	86.0	(53.2-131.5)
Female	2	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.6	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	5	2.2	226.6	(73.0-528.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.9	nc	(nc-nc)
Male	3	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	87	91.7	94.9	(76.0-117.0)
Female	2	0.8	nc	(nc-nc)	Female	98	93.6	104.7	(85.0-127.6)
<b><u>Lung and Bronchus</u></b>									
Male	10	12.3	81.6	(39.1-150.0)					
Female	20	12.7	157.4	(96.1-243.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	45.9	104.6	(77.1-138.6)	Male	24	30.6	78.5	(50.3-116.9)
Female	25	18.8	132.9	(86.0-196.1)	Female	25	26.4	94.7	(61.3-139.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	9.6	125.1	(64.5-218.5)	Male	10	9.5	104.8	(50.2-192.8)
Female	13	8.2	157.9	(84.0-270.0)	Female	8	8.4	95.0	(40.9-187.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	29	27.4	105.8	(70.8-151.9)
Female	188	205.9	91.3	(78.7-105.3)	Female	25	26.1	95.6	(61.9-141.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	7.1	113.4	(48.8-223.4)	Male	18	22.7	79.2	(46.9-125.1)
<b><u>Colon / Rectum</u></b>					Female	6	11.0	54.8	(20.0-119.3)
Male	48	51.0	94.1	(69.4-124.8)	<b><u>Ovary</u></b>				
Female	55	57.1	96.4	(72.6-125.4)	Female	11	18.2	60.3	(30.1-107.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	12.6	55.7	(22.3-114.8)	Male	17	16.5	103.1	(60.0-165.1)
Female	1	3.6	nc	(nc-nc)	Female	18	18.9	95.4	(56.5-150.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	3.8	158.2	(57.8-344.2)	Male	171	162.5	105.2	(90.0-122.2)
Female	2	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	11.0	127.2	(69.5-213.4)
Male	22	26.6	82.6	(51.8-125.1)	Female	5	7.3	68.2	(22.0-159.2)
Female	19	16.4	115.9	(69.7-180.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	6.9	158.8	(79.2-284.2)
Male	7	7.4	94.5	(37.9-194.8)	<b><u>Thyroid</u></b>				
Female	4	2.4	nc	(nc-nc)	Male	17	12.5	135.5	(78.9-217.0)
<b><u>Leukemia</u></b>					Female	37	38.2	96.9	(68.2-133.6)
Male	24	19.2	125.3	(80.2-186.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	15.3	123.8	(74.5-193.4)	Female	47	46.0	102.3	(75.1-136.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	16.8	89.1	(49.8-147.0)	Male	643	625.4	102.8	(95.0-111.1)
Female	5	5.9	84.8	(27.3-198.0)	Female	708	699.9	101.2	(93.8-108.9)
<b><u>Lung and Bronchus</u></b>									
Male	99	83.0	119.3	(97.0-145.3)					
Female	121	98.8	122.5	(101.6-146.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	24.0	120.9	(80.9-173.6)	Male	21	16.0	131.3	(81.2-200.7)
Female	13	8.1	159.8	(85.0-273.2)	Female	13	12.5	104.4	(55.5-178.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.0	100.6	(32.4-234.8)	Male	5	5.0	99.5	(32.1-232.3)
Female	5	3.9	129.7	(41.8-302.7)	Female	7	3.8	185.8	(74.4-382.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	14	14.3	98.0	(53.5-164.5)
Female	115	99.2	116.0	(95.8-139.2)	Female	9	11.8	76.5	(34.9-145.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.4	146.8	(47.3-342.6)	Male	10	12.1	82.6	(39.6-152.0)
<b><u>Colon / Rectum</u></b>					Female	9	5.1	177.3	(80.9-336.6)
Male	39	26.6	146.4	(104.1-200.2)	<b><u>Ovary</u></b>				
Female	29	24.7	117.4	(78.6-168.6)	Female	10	8.7	115.0	(55.1-211.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.8	88.7	(32.4-193.0)	Male	13	8.7	149.5	(79.5-255.6)
Female	3	1.6	nc	(nc-nc)	Female	6	8.1	73.7	(26.9-160.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	99	91.7	107.9	(87.7-131.4)
Female	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.8	104.2	(38.1-226.9)
Male	17	14.4	118.3	(68.9-189.4)	Female	0	3.2	nc	(nc-nc)
Female	3	7.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.3	150.7	(48.6-351.8)
Male	3	4.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	5	1.2	422.8	(136.3-986.7)	Male	8	6.5	122.4	(52.7-241.2)
<b><u>Leukemia</u></b>					Female	26	18.8	138.0	(90.1-202.2)
Male	12	9.9	121.4	(62.6-212.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	6.8	249.8	(145.4-399.9)	Female	30	22.8	131.6	(88.8-187.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	8.8	158.6	(86.6-266.2)	Male	378	334.6	113.0	(101.9-125.0)
Female	7	2.7	261.3	(104.7-538.4)	Female	408	324.4	125.8	(113.9-138.6)
<b><u>Lung and Bronchus</u></b>									
Male	47	44.6	105.4	(77.5-140.2)					
Female	69	44.4	155.5	(121.0-196.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	12.2	65.4	(28.1-128.8)
Female	0	0.1	nc	(nc-nc)	Female	7	8.4	83.2	(33.4-171.5)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.8	nc	(nc-nc)					
Female	2	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	10.2	147.1	(82.3-242.7)	Male	8	7.2	110.9	(47.8-218.6)
Female	3	2.5	nc	(nc-nc)	Female	5	3.8	130.7	(42.1-304.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.4	155.2	(74.3-285.4)
Female	36	31.4	114.5	(80.2-158.6)	Female	7	3.7	188.9	(75.7-389.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	5	5.6	88.5	(28.5-206.6)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	11	11.8	93.3	(46.5-167.0)	<b><u>Ovary</u></b>				
Female	13	7.6	171.0	(91.0-292.5)	Female	0	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	42	40.5	103.6	(74.7-140.1)
Female	2	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.5	197.6	(63.7-461.2)
Male	3	6.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	5	2.4	207.2	(66.8-483.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.0	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.8	103.6	(37.8-225.5)
Male	5	4.4	114.8	(37.0-267.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	8	7.3	109.3	(47.0-215.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	159	148.6	107.0	(91.0-125.0)
Female	0	0.9	nc	(nc-nc)	Female	126	101.9	123.7	(103.0-147.3)
<b><u>Lung and Bronchus</u></b>									
Male	18	18.9	95.0	(56.3-150.2)					
Female	19	14.2	134.1	(80.7-209.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	26.1	183.8	(135.5-243.7)	Male	10	17.5	57.2	(27.4-105.3)
Female	13	9.3	139.1	(74.0-237.9)	Female	16	14.2	113.0	(64.5-183.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.6	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	7	4.3	164.7	(66.0-339.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	19	15.7	120.7	(72.6-188.5)
Female	99	108.7	91.1	(74.1-110.9)	Female	22	13.5	163.5	(102.5-247.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.9	nc	(nc-nc)	Male	12	12.9	93.2	(48.1-162.9)
<b><u>Colon / Rectum</u></b>					Female	6	5.7	105.8	(38.6-230.4)
Male	29	29.5	98.3	(65.8-141.2)	<b><u>Ovary</u></b>				
Female	35	28.9	120.9	(84.2-168.2)	Female	10	9.6	104.4	(50.0-192.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	7.0	128.6	(58.7-244.2)	Male	7	9.3	74.9	(30.0-154.3)
Female	1	1.8	nc	(nc-nc)	Female	6	9.4	63.7	(23.3-138.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	115	89.0	129.3	(106.7-155.2)
Female	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	6.3	223.1	(121.9-374.4)
Male	14	15.1	92.6	(50.6-155.4)	Female	1	3.7	nc	(nc-nc)
Female	10	8.5	117.9	(56.4-216.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.4	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	3	7.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	19	21.6	88.0	(52.9-137.4)
Male	11	11.1	99.4	(49.6-177.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	8.0	149.5	(77.2-261.2)	Female	26	24.2	107.5	(70.2-157.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	9.3	nc	(nc-nc)	Male	379	352.9	107.4	(96.9-118.8)
Female	1	3.0	nc	(nc-nc)	Female	388	363.9	106.6	(96.3-117.8)
<b><u>Lung and Bronchus</u></b>									
Male	42	46.5	90.4	(65.1-122.2)					
Female	65	49.2	132.1	(101.9-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	14.7	95.1	(52.0-159.6)	Male	4	9.7	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	Female	5	7.6	65.5	(21.1-152.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	5	3.0	164.9	(53.1-384.8)
Female	0	2.4	nc	(nc-nc)	Female	6	2.4	248.7	(90.8-541.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.6	161.9	(88.5-271.7)
Female	59	60.3	97.8	(74.5-126.2)	Female	3	7.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.1	nc	(nc-nc)	Male	10	7.2	138.7	(66.4-255.0)
<b><u>Colon / Rectum</u></b>					Female	3	3.2	nc	(nc-nc)
Male	8	16.1	49.8	(21.5-98.2)	<b><u>Ovary</u></b>				
Female	13	15.9	81.8	(43.5-139.9)	Female	6	5.3	112.9	(41.2-245.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.1	147.5	(53.9-321.1)	Male	6	5.3	113.0	(41.3-245.9)
Female	3	1.0	nc	(nc-nc)	Female	11	5.2	210.1	(104.7-375.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	61	54.1	112.8	(86.3-144.9)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.5	nc	(nc-nc)
Male	13	8.6	150.9	(80.3-258.1)	Female	3	2.0	nc	(nc-nc)
Female	7	4.8	146.8	(58.8-302.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	7	3.9	179.5	(71.9-369.8)
<b><u>Leukemia</u></b>					Female	8	11.3	70.7	(30.4-139.2)
Male	6	5.9	101.0	(36.9-219.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.3	139.3	(50.9-303.3)	Female	10	13.8	72.4	(34.6-133.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.2	135.8	(54.4-279.8)	Male	234	200.5	116.7	(102.2-132.6)
Female	1	1.7	nc	(nc-nc)	Female	201	201.8	99.6	(86.3-114.3)
<b><u>Lung and Bronchus</u></b>									
Male	45	27.1	165.9	(121.0-222.0)					
Female	32	28.3	113.2	(77.4-159.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	6.7	164.9	(82.2-295.0)	Male	4	4.9	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	5	4.3	116.5	(37.5-271.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.4	114.7	(37.0-267.7)
Female	33	34.1	96.7	(66.6-135.8)	Female	3	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	6	4.0	150.3	(54.9-327.1)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	9	8.3	108.4	(49.5-205.8)	<b><u>Ovary</u></b>				
Female	12	8.6	140.2	(72.3-244.9)	Female	1	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	35	26.8	130.4	(90.8-181.3)
Female	3	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	7	4.5	155.1	(62.1-319.5)	Female	0	1.1	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	6.5	245.2	(140.1-398.2)
Male	4	2.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.4	nc	(nc-nc)	Female	6	7.8	77.1	(28.2-167.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	119	100.2	118.8	(98.4-142.1)
Female	1	0.9	nc	(nc-nc)	Female	120	111.8	107.4	(89.0-128.4)
<b><u>Lung and Bronchus</u></b>									
Male	12	12.8	93.8	(48.4-163.9)					
Female	15	15.4	97.7	(54.6-161.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	10	11.1	90.4	(43.3-166.2)	Female	2	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	11	7.7	142.8	(71.2-255.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	35	29.3	119.5	(83.2-166.1)
Female	1	0.3	nc	(nc-nc)	Female	33	34.9	94.6	(65.1-132.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.4	nc	(nc-nc)					
Female	9	4.4	205.1	(93.6-389.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	26.1	76.7	(46.9-118.5)	Male	30	16.8	179.0	(120.8-255.6)
Female	7	10.8	64.6	(25.9-133.1)	Female	26	14.7	176.5	(115.3-258.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	6	5.2	115.0	(42.0-250.2)
Female	8	4.7	169.8	(73.1-334.6)	Female	13	4.8	270.8	(144.1-463.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	13	15.2	85.6	(45.5-146.4)
Female	115	114.6	100.4	(82.9-120.5)	Female	11	14.9	74.0	(36.9-132.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.8	nc	(nc-nc)	Male	9	12.1	74.1	(33.8-140.7)
<b><u>Colon / Rectum</u></b>					Female	4	6.2	nc	(nc-nc)
Male	25	28.7	87.0	(56.3-128.4)	<b><u>Ovary</u></b>				
Female	39	32.8	118.9	(84.5-162.5)	Female	17	10.3	165.7	(96.4-265.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.8	88.3	(32.3-192.3)	Male	11	9.2	119.1	(59.4-213.1)
Female	3	2.1	nc	(nc-nc)	Female	10	10.9	91.9	(44.0-169.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	117	85.8	136.4	(112.8-163.5)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.1	nc	(nc-nc)
Male	9	14.3	63.0	(28.8-119.7)	Female	6	4.2	141.7	(51.7-308.4)
Female	14	9.2	152.0	(83.0-255.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.7	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	6	6.6	90.6	(33.1-197.2)
<b><u>Leukemia</u></b>					Female	33	20.8	158.4	(109.0-222.5)
Male	12	10.8	111.1	(57.3-194.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.8	102.0	(46.5-193.6)	Female	39	25.5	152.8	(108.6-208.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	9.0	nc	(nc-nc)	Male	350	341.7	102.4	(92.0-113.8)
Female	2	3.4	nc	(nc-nc)	Female	435	394.5	110.3	(100.1-121.1)
<b><u>Lung and Bronchus</u></b>									
Male	33	45.7	72.2	(49.7-101.3)					
Female	48	56.1	85.5	(63.1-113.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	10.1	88.8	(40.5-168.6)	Male	8	6.7	118.7	(51.1-233.9)
Female	2	2.9	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.0	nc	(nc-nc)
Female	43	38.1	112.8	(81.6-152.0)	Female	6	4.4	137.2	(50.1-298.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	1	5.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.9	nc	(nc-nc)
Male	9	11.3	79.9	(36.5-151.7)	<b><u>Ovary</u></b>				
Female	3	8.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	33	39.3	84.0	(57.8-117.9)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	7	6.1	114.9	(46.0-236.7)	Female	1	1.1	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	7.3	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.4	nc	(nc-nc)	Female	8	9.2	86.6	(37.3-170.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.9	128.5	(41.4-300.0)	Male	119	141.8	83.9	(69.5-100.4)
Female	0	1.0	nc	(nc-nc)	Female	103	121.4	84.8	(69.2-102.9)
<b><u>Lung and Bronchus</u></b>									
Male	14	18.8	74.3	(40.6-124.6)					
Female	12	16.4	73.1	(37.7-127.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.8	81.8	(35.2-161.1)	Male	8	6.2	128.9	(55.5-254.0)
Female	6	3.7	162.0	(59.1-352.6)	Female	1	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.8	278.3	(89.7-649.6)	Male	2	2.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	89.8	(28.9-209.5)
Female	35	40.8	85.8	(59.7-119.3)	Female	3	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.2	nc	(nc-nc)
Male	10	10.5	95.1	(45.5-174.9)	<b><u>Ovary</u></b>				
Female	14	11.1	126.5	(69.1-212.3)	Female	6	3.7	163.4	(59.7-355.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	25	33.0	75.8	(49.1-111.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.3	nc	(nc-nc)
Male	5	5.3	94.6	(30.5-220.8)	Female	1	1.4	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	7.2	nc	(nc-nc)
Male	6	3.9	155.8	(56.9-339.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.0	nc	(nc-nc)	Female	11	9.7	113.2	(56.4-202.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	116	127.3	91.1	(75.3-109.3)
Female	0	1.2	nc	(nc-nc)	Female	120	138.2	86.8	(72.0-103.8)
<b><u>Lung and Bronchus</u></b>									
Male	20	17.2	116.1	(70.9-179.3)					
Female	15	19.5	77.1	(43.1-127.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	18.3	60.3	(30.0-107.8)
Female	0	0.1	nc	(nc-nc)	Female	11	12.8	86.0	(42.9-153.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.6	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	4.2	165.1	(66.1-340.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	15.4	91.1	(49.8-152.8)
Female	0	0.1	nc	(nc-nc)	Female	6	13.3	45.0	(16.4-97.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.0	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.5	154.8	(62.0-318.9)	Male	11	2.9	385.5	(192.2-689.9)
Female	3	2.2	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	16	20.3	78.9	(45.1-128.2)	Female	2	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.2	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	6.6	75.9	(24.5-177.1)	Female	1	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	15.8	126.8	(77.4-195.9)
Female	2	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.2	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	6	4.7	128.9	(47.1-280.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	73	59.3	123.1	(96.5-154.8)
Female	1	0.7	nc	(nc-nc)	Female	59	72.8	81.0	(61.7-104.5)
<b><u>Lung and Bronchus</u></b>									
Male	9	8.1	110.9	(50.6-210.5)					
Female	6	10.7	55.9	(20.4-121.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.6	75.3	(32.4-148.4)	Male	20	7.2	278.8	(170.2-430.6)
Female	2	3.3	nc	(nc-nc)	Female	21	5.2	407.0	(251.8-622.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	6	2.2	268.6	(98.1-584.7)
Female	2	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	58	39.5	146.9	(111.5-189.9)	Female	5	4.8	103.4	(33.3-241.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	10	5.2	190.6	(91.3-350.6)
<b><u>Colon / Rectum</u></b>					Female	4	2.1	nc	(nc-nc)
Male	8	11.7	68.1	(29.3-134.2)	<b><u>Ovary</u></b>				
Female	11	10.1	108.7	(54.2-194.4)	Female	3	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	5	3.8	132.0	(42.6-308.1)
Female	4	0.7	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	29	36.9	78.5	(52.6-112.7)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	3	6.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.0	124.6	(59.7-229.2)
Male	8	4.4	182.3	(78.5-359.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.9	nc	(nc-nc)	Female	11	9.0	122.0	(60.8-218.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	136	144.3	94.3	(79.1-111.5)
Female	0	1.1	nc	(nc-nc)	Female	162	131.8	123.0	(104.8-143.4)
<b><u>Lung and Bronchus</u></b>									
Male	13	19.2	67.6	(35.9-115.6)					
Female	16	18.0	89.1	(50.9-144.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	35.1	94.0	(64.7-132.1)	Male	21	22.8	92.1	(57.0-140.8)
Female	10	13.0	76.9	(36.8-141.4)	Female	21	18.9	111.0	(68.7-169.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	7.0	143.1	(68.5-263.2)	Male	5	7.1	70.4	(22.7-164.3)
Female	8	5.8	137.3	(59.1-270.6)	Female	4	5.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	14	20.4	68.6	(37.5-115.1)
Female	154	151.5	101.6	(86.2-119.0)	Female	17	18.4	92.2	(53.7-147.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	5.2	nc	(nc-nc)	Male	16	16.3	98.1	(56.0-159.3)
<b><u>Colon / Rectum</u></b>					Female	11	7.8	140.3	(70.0-251.1)
Male	46	38.1	120.8	(88.4-161.1)	<b><u>Ovary</u></b>				
Female	36	39.6	91.0	(63.7-126.0)	Female	21	13.2	159.1	(98.4-243.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.2	130.2	(67.2-227.4)	Male	10	12.3	81.1	(38.8-149.2)
Female	4	2.5	nc	(nc-nc)	Female	9	12.9	69.7	(31.8-132.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	110	114.8	95.8	(78.7-115.5)
Female	2	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	8.3	157.2	(83.6-268.8)
Male	17	19.3	88.2	(51.3-141.2)	Female	2	5.0	nc	(nc-nc)
Female	12	11.8	101.3	(52.3-177.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	5.0	139.0	(55.7-286.3)
Male	4	5.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	1.8	nc	(nc-nc)	Male	16	9.0	178.2	(101.8-289.3)
<b><u>Leukemia</u></b>					Female	25	28.1	89.0	(57.6-131.4)
Male	11	14.4	76.6	(38.2-137.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	10.6	65.9	(26.4-135.7)	Female	38	34.0	111.6	(79.0-153.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	12.1	49.7	(18.2-108.2)	Male	445	459.4	96.9	(88.1-106.3)
Female	3	4.2	nc	(nc-nc)	Female	493	501.7	98.3	(89.8-107.3)
<b><u>Lung and Bronchus</u></b>									
Male	51	62.2	82.0	(61.0-107.8)					
Female	63	70.0	89.9	(69.1-115.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	37.6	95.8	(67.1-132.7)	Male	35	22.7	154.5	(107.6-214.8)
Female	12	13.3	89.9	(46.4-157.1)	Female	15	17.2	87.2	(48.8-143.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.5	138.6	(63.2-263.1)	Male	8	7.2	111.8	(48.2-220.4)
Female	11	5.4	202.0	(100.7-361.4)	Female	4	5.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	22	20.4	107.7	(67.5-163.0)
Female	157	135.6	115.8	(98.4-135.4)	Female	15	17.9	83.6	(46.8-137.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.4	nc	(nc-nc)	Male	13	15.7	82.8	(44.0-141.6)
<b><u>Colon / Rectum</u></b>					Female	7	7.5	93.3	(37.4-192.2)
Male	29	39.5	73.4	(49.1-105.4)	<b><u>Ovary</u></b>				
Female	35	40.6	86.2	(60.1-119.9)	Female	12	12.3	97.9	(50.5-171.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	9.3	64.3	(23.5-140.1)	Male	9	12.9	69.6	(31.8-132.2)
Female	2	2.6	nc	(nc-nc)	Female	19	13.7	138.8	(83.5-216.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	134	114.2	117.4	(98.3-139.0)
Female	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.6	58.2	(18.8-135.9)
Male	14	18.6	75.4	(41.2-126.5)	Female	2	5.3	nc	(nc-nc)
Female	11	10.8	101.4	(50.6-181.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.5	142.6	(46.0-332.9)
Male	2	5.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	9	7.9	114.2	(52.1-216.8)
<b><u>Leukemia</u></b>					Female	36	22.9	157.4	(110.2-217.9)
Male	11	14.5	75.6	(37.7-135.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	10.6	141.1	(78.9-232.7)	Female	28	30.6	91.7	(60.9-132.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	11.8	nc	(nc-nc)	Male	425	462.0	92.0	(83.4-101.2)
Female	1	4.0	nc	(nc-nc)	Female	464	470.3	98.7	(89.9-108.1)
<b><u>Lung and Bronchus</u></b>									
Male	41	63.9	64.2	(46.1-87.1)					
Female	39	65.9	59.2	(42.1-80.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	111	98.2	113.0	(93.0-136.1)	Male	30	62.0	48.4	(32.6-69.1)
Female	37	39.4	93.9	(66.1-129.4)	Female	18	53.1	33.9	(20.1-53.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	18.7	96.0	(56.9-151.8)	Male	21	19.4	108.3	(67.0-165.5)
Female	14	16.8	83.2	(45.4-139.6)	Female	13	17.3	75.0	(39.9-128.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	48	55.4	86.7	(63.9-115.0)
Female	345	397.0	86.9	(78.0-96.6)	Female	43	53.3	80.7	(58.4-108.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	22	13.6	161.8	(101.4-245.0)	Male	54	42.8	126.1	(94.7-164.5)
<b><u>Colon / Rectum</u></b>					Female	28	22.0	127.1	(84.5-183.8)
Male	118	103.5	114.0	(94.4-136.5)	<b><u>Ovary</u></b>				
Female	111	118.9	93.4	(76.8-112.5)	Female	32	36.3	88.2	(60.3-124.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	31	25.2	123.1	(83.6-174.7)	Male	37	33.9	109.1	(76.8-150.3)
Female	11	7.5	147.2	(73.4-263.5)	Female	58	39.8	145.6	(110.6-188.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	10	7.6	131.7	(63.0-242.2)	Male	334	314.4	106.2	(95.1-118.3)
Female	3	6.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	40	22.7	176.5	(126.1-240.4)
Male	60	51.4	116.6	(89.0-150.1)	Female	25	15.5	161.6	(104.5-238.5)
Female	40	32.5	122.9	(87.8-167.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	14.1	64.0	(29.2-121.5)
Male	27	14.6	185.4	(122.1-269.7)	<b><u>Thyroid</u></b>				
Female	12	4.8	250.9	(129.5-438.3)	Male	18	23.2	77.5	(45.9-122.5)
<b><u>Leukemia</u></b>					Female	79	74.2	106.5	(84.3-132.7)
Male	32	39.4	81.3	(55.6-114.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	32.2	65.1	(40.3-99.6)	Female	89	88.8	100.3	(80.5-123.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	65	32.2	201.6	(155.6-256.9)	Male	1418	1256.5	112.9	(107.1-118.9)
Female	10	11.9	83.7	(40.1-153.9)	Female	1349	1399.5	96.4	(91.3-101.7)
<b><u>Lung and Bronchus</u></b>									
Male	251	173.8	144.4	(127.1-163.4)					
Female	207	198.7	104.2	(90.5-119.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	15.7	89.4	(48.9-150.1)
Female	0	0.1	nc	(nc-nc)	Female	13	14.1	92.4	(49.1-158.0)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.0	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	10	8.7	115.6	(55.3-212.6)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.5	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	9.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	35.8	42.0	(23.5-69.2)
Female	0	0.2	nc	(nc-nc)	Female	22	28.8	76.5	(47.9-115.8)
<b><u>Lung and Bronchus</u></b>									
Male	0	5.0	nc	(nc-nc)					
Female	2	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	15.8	76.1	(39.3-133.0)
Female	0	0.1	nc	(nc-nc)	Female	11	16.1	68.3	(34.1-122.3)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.1	nc	(nc-nc)					
Female	0	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;